Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 2.8% - Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s share price fell 2.8% during trading on Friday . The stock traded as low as $33.01 and last traded at $33.58. 160,971 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 916,872 shares. The stock had previously closed at $34.54.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Noble Financial reiterated an "outperform" rating and set a $70.00 price target on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th. Alliance Global Partners restated a "buy" rating on shares of Tonix Pharmaceuticals in a report on Tuesday, June 3rd. Finally, Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th.

Tonix Pharmaceuticals Stock Performance

The company has a fifty day moving average of $25.07 and a two-hundred day moving average of $23.62. The stock has a market capitalization of $234.25 million, a P/E ratio of -0.01 and a beta of 2.09. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($2.84) EPS for the quarter, beating analysts' consensus estimates of ($3.23) by $0.39. The company had revenue of $2.43 million during the quarter, compared to the consensus estimate of $2.55 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current year.

Insider Buying and Selling

In other Tonix Pharmaceuticals news, CEO Seth Lederman bought 4,000 shares of the business's stock in a transaction on Thursday, May 15th. The shares were purchased at an average price of $21.55 per share, with a total value of $86,200.00. Following the purchase, the chief executive officer now directly owns 4,005 shares of the company's stock, valued at approximately $86,307.75. The trade was a 80,000.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.03% of the company's stock.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Commonwealth Equity Services LLC bought a new position in Tonix Pharmaceuticals during the fourth quarter valued at about $40,000. Two Sigma Investments LP acquired a new stake in Tonix Pharmaceuticals during the 4th quarter valued at $66,000. Northern Trust Corp purchased a new stake in Tonix Pharmaceuticals in the 4th quarter worth about $162,000. IFP Advisors Inc acquired a new stake in shares of Tonix Pharmaceuticals during the first quarter worth approximately $179,000. Finally, Rhumbline Advisers purchased a new position in shares of Tonix Pharmaceuticals during the 1st quarter valued at $244,000. Institutional investors own 82.26% of the company's stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.